516 related articles for article (PubMed ID: 10171148)
1. Permeation enhancers compatible with transdermal drug delivery systems. Part I: selection and formulation considerations.
Pfister WR; Hsieh DS
Med Device Technol; 1990; 1(5):48-55. PubMed ID: 10171148
[TBL] [Abstract][Full Text] [Related]
2. Permeation enhancers compatible with transdermal drug delivery systems: part II: system design considerations.
Pfister WR; Hsieh DS
Med Device Technol; 1990; 1(6):28-33. PubMed ID: 10171149
[TBL] [Abstract][Full Text] [Related]
3. Design and in vivo evaluation of an indapamide transdermal patch.
Ren C; Fang L; Ling L; Wang Q; Liu S; Zhao L; He Z
Int J Pharm; 2009 Mar; 370(1-2):129-35. PubMed ID: 19114099
[TBL] [Abstract][Full Text] [Related]
4. Penetration enhancers.
Williams AC; Barry BW
Adv Drug Deliv Rev; 2004 Mar; 56(5):603-18. PubMed ID: 15019749
[TBL] [Abstract][Full Text] [Related]
5. The use of polymers for dermal and transdermal delivery.
Valenta C; Auner BG
Eur J Pharm Biopharm; 2004 Sep; 58(2):279-89. PubMed ID: 15296955
[TBL] [Abstract][Full Text] [Related]
6. Ammonium carbamates as highly active transdermal permeation enhancers with a dual mechanism of action.
Novotný M; Klimentová J; Janůšová B; Palát K; Hrabálek A; Vávrová K
J Control Release; 2011 Mar; 150(2):164-70. PubMed ID: 21093505
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in transdermal drug delivery.
Subedi RK; Oh SY; Chun MK; Choi HK
Arch Pharm Res; 2010 Mar; 33(3):339-51. PubMed ID: 20361297
[TBL] [Abstract][Full Text] [Related]
8. Development of transdermal therapeutic formulation of CNS5161, a novel NMDA receptor antagonist, by utilizing pressure-sensitive adhesives II: improved transdermal absorption and evaluation of efficacy and safety.
Naruse M; Ogawara K; Kimura T; Konishi R; Higaki K
Eur J Pharm Sci; 2014 Feb; 52():86-94. PubMed ID: 24215737
[TBL] [Abstract][Full Text] [Related]
9. Effect of permeation enhancers on the release of ketoprofen through transdermal drug delivery systems.
Singh SK; Durrani MJ; Reddy IK; Khan MA
Pharmazie; 1996 Oct; 51(10):741-4. PubMed ID: 8941942
[TBL] [Abstract][Full Text] [Related]
10. Drug in adhesive type transdermal matrix systems of ondansetron hydrochloride: optimization of permeation pattern using response surface methodology.
Swain K; Pattnaik S; Sahu SC; Patnaik KK; Mallick S
J Drug Target; 2010 Feb; 18(2):106-14. PubMed ID: 19712026
[TBL] [Abstract][Full Text] [Related]
11. Transdermal delivery systems.
Merkle HP
Methods Find Exp Clin Pharmacol; 1989 Mar; 11(3):135-53. PubMed ID: 2657273
[TBL] [Abstract][Full Text] [Related]
12. Transdermal delivery system for zidovudine: in vitro, ex vivo and in vivo evaluation.
Narishetty ST; Panchagnula R
Biopharm Drug Dispos; 2004 Jan; 25(1):9-20. PubMed ID: 14716748
[TBL] [Abstract][Full Text] [Related]
13. Status of terpenes as skin penetration enhancers.
Aqil M; Ahad A; Sultana Y; Ali A
Drug Discov Today; 2007 Dec; 12(23-24):1061-7. PubMed ID: 18061886
[TBL] [Abstract][Full Text] [Related]
14. Enhanced transdermal delivery of loratadine from the EVA matrix.
Cho CW; Choi JS; Kim SJ; Shin SC
Drug Deliv; 2009 May; 16(4):230-5. PubMed ID: 19514983
[TBL] [Abstract][Full Text] [Related]
15. Transdermal patches for site-specific delivery of anastrozole: In vitro and local tissue disposition evaluation.
Xi H; Yang Y; Zhao D; Fang L; Sun L; Mu L; Liu J; Zhao N; Zhao Y; Zheng N; He Z
Int J Pharm; 2010 May; 391(1-2):73-8. PubMed ID: 20170718
[TBL] [Abstract][Full Text] [Related]
16. Effect of penetration enhancers on the release and skin permeation of bupranolol from reservoir-type transdermal delivery systems.
Babu RJ; Pandit JK
Int J Pharm; 2005 Jan; 288(2):325-34. PubMed ID: 15620873
[TBL] [Abstract][Full Text] [Related]
17. Natural products as potential drug permeation enhancer in transdermal drug delivery system.
Patil UK; Saraogi R
Arch Dermatol Res; 2014 Jul; 306(5):419-26. PubMed ID: 24481830
[TBL] [Abstract][Full Text] [Related]
18. Skin permeation of ketotifen applied from stick-type formulation.
Kimura C; Nakanishi T; Tojo K
Eur J Pharm Biopharm; 2007 Sep; 67(2):420-4. PubMed ID: 17433642
[TBL] [Abstract][Full Text] [Related]
19. Development and in vitro evaluation of furosemide transdermal formulations using experimental design techniques.
Agyralides GG; Dallas PP; Rekkas DM
Int J Pharm; 2004 Aug; 281(1-2):35-43. PubMed ID: 15288341
[TBL] [Abstract][Full Text] [Related]
20. Chiral 4-
Chu T; Wang C; Wang J; Wang H; Geng D; Wu C; Zhao L; Zhao L
Drug Deliv; 2020 Dec; 27(1):723-735. PubMed ID: 32397753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
